English

Coley Pharmaceutical Group, Inc.

EDGAR

Quarterly report (10-Q) · filed 2007-11-02

11 filing records in this dataset, filed from 2005-09-16 to 2007-11-02. Explore the available filing history and original sources.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

5.11 million USD

2007-09-30 · USD

Exact inputs and evidence

Revenue: 5112000 USD Source

Operating margin

-133.55%

2007-09-30 · %

Exact inputs and evidence

Operating Income: -6827000 USD Source
Revenue: 5112000 USD Source

Operating cash flow

-7.5 million USD

2007-09-30 · USD

Exact inputs and evidence

Operating Cash Flow: -13409000 USD Source
Operating Cash Flow: -5905000 USD Source

Free cash flow

-8.61 million USD

2007-09-30 · USD

Exact inputs and evidence

Operating Cash Flow: -13409000 USD Source
Operating Cash Flow: -5905000 USD Source
Capital Expenditure: 1532000 USD Source
Capital Expenditure: 423000 USD Source

Cash and cash equivalents: 70 million USD 2007-09-30 Source
Exact value

69985000 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

31.2 million USD

2006-10-01 – 2007-09-30

Exact inputs and evidence

Revenue: 20201000 USD · 2006-01-01 – 2006-12-31 Source
Revenue: 15014000 USD · 2006-01-01 – 2006-09-30 Source
Revenue: 5523000 USD · 2007-01-01 – 2007-03-31 Source
Revenue: 15357000 USD · 2007-04-01 – 2007-06-30 Source
Revenue: 5112000 USD · 2007-07-01 – 2007-09-30 Source

Net income

-33.3 million USD

2006-10-01 – 2007-09-30

Exact inputs and evidence

Net income: -29775000 USD · 2006-01-01 – 2006-12-31 Source
Net income: -24604000 USD · 2006-01-01 – 2006-09-30 Source
Net income: -7715000 USD · 2007-01-01 – 2007-03-31 Source
Net income: -14020000 USD · 2007-04-01 – 2007-06-30 Source
Net income: -6421000 USD · 2007-07-01 – 2007-09-30 Source

Operating cash flow

-20.8 million USD

2006-10-01 – 2007-09-30

Exact inputs and evidence

Operating cash flow: -35678000 USD · 2006-01-01 – 2006-12-31 Source
Operating cash flow: -28335000 USD · 2006-01-01 – 2006-09-30 Source
Operating cash flow: -9395000 USD · 2007-01-01 – 2007-03-31 Source
Operating cash flow: -5905000 USD · 2007-01-01 – 2007-06-30 Source
Operating cash flow: -9395000 USD · 2007-01-01 – 2007-03-31 Source
Operating cash flow: -13409000 USD · 2007-01-01 – 2007-09-30 Source
Operating cash flow: -5905000 USD · 2007-01-01 – 2007-06-30 Source

Capital expenditure

1.67 million USD

2006-10-01 – 2007-09-30

Exact inputs and evidence

Capital expenditure: 811000 USD · 2006-01-01 – 2006-12-31 Source
Capital expenditure: 672000 USD · 2006-01-01 – 2006-09-30 Source
Capital expenditure: 56000 USD · 2007-01-01 – 2007-03-31 Source
Capital expenditure: 423000 USD · 2007-01-01 – 2007-06-30 Source
Capital expenditure: 56000 USD · 2007-01-01 – 2007-03-31 Source
Capital expenditure: 1532000 USD · 2007-01-01 – 2007-09-30 Source
Capital expenditure: 423000 USD · 2007-01-01 – 2007-06-30 Source

Free cash flow

-22.4 million USD

2006-10-01 – 2007-09-30

Exact inputs and evidence

Operating cash flow: -35678000 USD · 2006-01-01 – 2006-12-31 Source
Operating cash flow: -28335000 USD · 2006-01-01 – 2006-09-30 Source
Operating cash flow: -9395000 USD · 2007-01-01 – 2007-03-31 Source
Operating cash flow: -5905000 USD · 2007-01-01 – 2007-06-30 Source
Operating cash flow: -9395000 USD · 2007-01-01 – 2007-03-31 Source
Operating cash flow: -13409000 USD · 2007-01-01 – 2007-09-30 Source
Operating cash flow: -5905000 USD · 2007-01-01 – 2007-06-30 Source
Capital expenditure: 811000 USD · 2006-01-01 – 2006-12-31 Source
Capital expenditure: 672000 USD · 2006-01-01 – 2006-09-30 Source
Capital expenditure: 56000 USD · 2007-01-01 – 2007-03-31 Source
Capital expenditure: 423000 USD · 2007-01-01 – 2007-06-30 Source
Capital expenditure: 56000 USD · 2007-01-01 – 2007-03-31 Source
Capital expenditure: 1532000 USD · 2007-01-01 – 2007-09-30 Source
Capital expenditure: 423000 USD · 2007-01-01 – 2007-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2007-11-02.

Financial data available through: 2006-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2006-12-31
Operating income: 4 of 11 periods available· newest 2006-12-31
Net income: 4 of 11 periods available· newest 2006-12-31
Operating cash flow: 4 of 11 periods available· newest 2006-12-31
Capital expenditure: 4 of 11 periods available· newest 2006-12-31
Total assets: 3 of 11 periods available· newest 2006-12-31
Total liabilities: 3 of 11 periods available· newest 2006-12-31
Current assets: 3 of 11 periods available· newest 2006-12-31
Current liabilities: 3 of 11 periods available· newest 2006-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2006-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+27.2%

Prior period

USD 15.88 million

2005-01-01 – 2005-12-31
Current period

USD 20.2 million

2006-01-01 – 2006-12-31

Exact inputs and evidence

20201000 − 15884000 = 4317000 USD

15884000 USD · 2005-01-01 – 2005-12-31
Inspect prior input Prior source
20201000 USD · 2006-01-01 – 2006-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Coley Pharmaceutical Group, Inc. · 2006-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Year-over-year change in Revenue: 4317000 USD Concept: fundies:Revenue Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 20201000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#8037 Input fundies:Revenue: 15884000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#8037
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 8.29 million

Prior period

−USD 38.06 million

2005-01-01 – 2005-12-31
Current period

−USD 29.78 million

2006-01-01 – 2006-12-31

Exact inputs and evidence

-29775000 − -38064000 = 8289000 USD

-38064000 USD · 2005-01-01 – 2005-12-31
Inspect prior input Prior source
-29775000 USD · 2006-01-01 – 2006-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Coley Pharmaceutical Group, Inc. · 2006-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Year-over-year change in Net income: 8289000 USD Concept: fundies:NetIncome Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -29775000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#9952 Input fundies:NetIncome: -38064000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#9952
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-420.6%

Prior period

USD 11.13 million

2005-01-01 – 2005-12-31
Current period

−USD 35.68 million

2006-01-01 – 2006-12-31

Exact inputs and evidence

-35678000 − 11128000 = -46806000 USD

11128000 USD · 2005-01-01 – 2005-12-31
Inspect prior input Prior source
-35678000 USD · 2006-01-01 – 2006-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Coley Pharmaceutical Group, Inc. · 2006-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Year-over-year change in Operating cash flow: -46806000 USD Concept: fundies:OperatingCashFlow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -35678000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10134 Input fundies:OperatingCashFlow: 11128000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10134
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+42.8%

Prior period

USD 568,000

2005-01-01 – 2005-12-31
Current period

USD 811,000

2006-01-01 – 2006-12-31

Exact inputs and evidence

811000 − 568000 = 243000 USD

568000 USD · 2005-01-01 – 2005-12-31
Inspect prior input Prior source
811000 USD · 2006-01-01 – 2006-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Coley Pharmaceutical Group, Inc. · 2006-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Year-over-year change in Capital expenditure: 243000 USD Concept: fundies:CapitalExpenditure Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 811000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10232 Input fundies:CapitalExpenditure: 568000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10232
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2006 2006-01-01 – 2006-12-31

Revenue USD 20.2 million 100% of revenue
Operating costs Derived USD 55.25 million 274% of revenue
Operating income −USD 35.05 million −174% of revenue
Tax, interest and other Derived −USD 5.28 million −26% of revenue
Net income −USD 29.78 million −147% of revenue

Cash

Operating cash flow −USD 35.68 million −177% of revenue
Capital expenditure USD 811,000 4% of revenue
Free cash flow Derived −USD 36.49 million −181% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2003 Operating loss: operating costs were 571% of revenue.
2004 Operating loss: operating costs were 333% of revenue.
2005 Operating loss: operating costs were 354% of revenue.
2006 Operating loss: operating costs were 274% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2003 2003-01-01 – 2003-12-31	6548000	37408000 Derived	-30860000	-350000 Derived	-30510000	-25380000 Derived	Source 2003-01-01 – 2003-12-31: 6548000 USD Inspect Revenue Open source 2003-01-01 – 2003-12-31: -30860000 USD Inspect Operating Income Open source 2003-01-01 – 2003-12-31: -30510000 USD Inspect Net Income Open source 2003-01-01 – 2003-12-31: -22425000 USD Inspect Operating Cash Flow Open source 2003-01-01 – 2003-12-31: 2955000 USD Inspect Capital Expenditure Open source
2004 2004-01-01 – 2004-12-31	14344000	47825000 Derived	-33481000	500000 Derived	-33981000	-28079000 Derived	Source 2004-01-01 – 2004-12-31: 14344000 USD Inspect Revenue Open source 2004-01-01 – 2004-12-31: -33481000 USD Inspect Operating Income Open source 2004-01-01 – 2004-12-31: -33981000 USD Inspect Net Income Open source 2004-01-01 – 2004-12-31: -27718000 USD Inspect Operating Cash Flow Open source 2004-01-01 – 2004-12-31: 361000 USD Inspect Capital Expenditure Open source
2005 2005-01-01 – 2005-12-31	15884000	56239000 Derived	-40355000	-2291000 Derived	-38064000	10560000 Derived	Source 2005-01-01 – 2005-12-31: 15884000 USD Inspect Revenue Open source 2005-01-01 – 2005-12-31: -40355000 USD Inspect Operating Income Open source 2005-01-01 – 2005-12-31: -38064000 USD Inspect Net Income Open source 2005-01-01 – 2005-12-31: 11128000 USD Inspect Operating Cash Flow Open source 2005-01-01 – 2005-12-31: 568000 USD Inspect Capital Expenditure Open source
2006 2006-01-01 – 2006-12-31	20201000	55254000 Derived	-35053000	-5278000 Derived	-29775000	-36489000 Derived	Source 2006-01-01 – 2006-12-31: 20201000 USD Inspect Revenue Open source 2006-01-01 – 2006-12-31: -35053000 USD Inspect Operating Income Open source 2006-01-01 – 2006-12-31: -29775000 USD Inspect Net Income Open source 2006-01-01 – 2006-12-31: -35678000 USD Inspect Operating Cash Flow Open source 2006-01-01 – 2006-12-31: 811000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 20.2M 2006

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20032003-12-31	Revenue	6548000	Revenue: 6548000 Open source
20042004-12-31	Revenue	14344000	Revenue: 14344000 Open source
20052005-12-31	Revenue	15884000	Revenue: 15884000 Open source
20062006-12-31	Revenue	20201000	Revenue: 20201000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

27.2% 2006

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20032003-12-31	Year over year	No prior comparable period	Revenue: 6548000 Open source
20042004-12-31	Year over year	119.1%	Revenue: 14344000 Open source Revenue: 6548000 Open source
20052005-12-31	Year over year	10.7%	Revenue: 15884000 Open source Revenue: 14344000 Open source
20062006-12-31	Year over year	27.2%	Revenue: 20201000 Open source Revenue: 15884000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -173.5% 2006

Net margin -147.4% 2006

Free cash flow margin -180.6% 2006

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20032003-12-31	Operating margin	-471.3%	Operating Income: -30860000 Open source Revenue: 6548000 Open source
20042004-12-31	Operating margin	-233.4%	Operating Income: -33481000 Open source Revenue: 14344000 Open source
20052005-12-31	Operating margin	-254.1%	Operating Income: -40355000 Open source Revenue: 15884000 Open source
20062006-12-31	Operating margin	-173.5%	Operating Income: -35053000 Open source Revenue: 20201000 Open source
20032003-12-31	Net margin	-465.9%	Net Income: -30510000 Open source Revenue: 6548000 Open source
20042004-12-31	Net margin	-236.9%	Net Income: -33981000 Open source Revenue: 14344000 Open source
20052005-12-31	Net margin	-239.6%	Net Income: -38064000 Open source Revenue: 15884000 Open source
20062006-12-31	Net margin	-147.4%	Net Income: -29775000 Open source Revenue: 20201000 Open source
20032003-12-31	Free cash flow margin	-387.6%	Revenue: 6548000 Open source Operating Cash Flow: -22425000 Open source Capital Expenditure: 2955000 Open source
20042004-12-31	Free cash flow margin	-195.8%	Revenue: 14344000 Open source Operating Cash Flow: -27718000 Open source Capital Expenditure: 361000 Open source
20052005-12-31	Free cash flow margin	66.5%	Revenue: 15884000 Open source Operating Cash Flow: 11128000 Open source Capital Expenditure: 568000 Open source
20062006-12-31	Free cash flow margin	-180.6%	Revenue: 20201000 Open source Operating Cash Flow: -35678000 Open source Capital Expenditure: 811000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -35.7M 2006

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20032003-12-31	Operating cash flow	-22425000	Operating Cash Flow: -22425000 Open source
20042004-12-31	Operating cash flow	-27718000	Operating Cash Flow: -27718000 Open source
20052005-12-31	Operating cash flow	11128000	Operating Cash Flow: 11128000 Open source
20062006-12-31	Operating cash flow	-35678000	Operating Cash Flow: -35678000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -36.5M 2006

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20032003-12-31	Free cash flow	-25380000	Operating Cash Flow: -22425000 Open source Capital Expenditure: 2955000 Open source
20042004-12-31	Free cash flow	-28079000	Operating Cash Flow: -27718000 Open source Capital Expenditure: 361000 Open source
20052005-12-31	Free cash flow	10560000	Operating Cash Flow: 11128000 Open source Capital Expenditure: 568000 Open source
20062006-12-31	Free cash flow	-36489000	Operating Cash Flow: -35678000 Open source Capital Expenditure: 811000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

42.2% 2006

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2003-12-31	Liabilities / assets	Not reported	No source recorded
20042004-12-31	Liabilities / assets	77.8%	Total Liabilities: 28078000 Open source Total Assets: 36090000 Open source
20052005-12-31	Liabilities / assets	41.8%	Total Liabilities: 67338000 Open source Total Assets: 161224000 Open source
20062006-12-31	Liabilities / assets	42.2%	Total Liabilities: 51633000 Open source Total Assets: 122275000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

4.62× 2006

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2003-12-31	Current assets / current liabilities	Not reported	No source recorded
20042004-12-31	Current assets / current liabilities	2.09×	Current Assets: 26148000 Open source Current Liabilities: 12507000 Open source
20052005-12-31	Current assets / current liabilities	6.02×	Current Assets: 148305000 Open source Current Liabilities: 24646000 Open source
20062006-12-31	Current assets / current liabilities	4.62×	Current Assets: 111349000 Open source Current Liabilities: 24103000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2003 2003-01-01 – 2003-12-31	−USD 30.51 million Exact value Exact value: -30510000 USD 2003-01-01 – 2003-12-31: -30510000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Coley Pharmaceutical Group, Inc. · 2003-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Net Income: -30510000 USD Concept: fundies:NetIncome Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197/explain?concept=fundies%3ANetIncome&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:NetIncome: -30510000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-06-061871.txt#10084 The citation records this snapshot. The page link may show a newer release later.	−USD 22.43 million Exact value Exact value: -22425000 USD 2003-01-01 – 2003-12-31: -22425000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Coley Pharmaceutical Group, Inc. · 2003-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Operating Cash Flow: -22425000 USD Concept: fundies:OperatingCashFlow Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197/explain?concept=fundies%3AOperatingCashFlow&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22425000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-06-061871.txt#10280 The citation records this snapshot. The page link may show a newer release later.	USD 2.96 million Exact value Exact value: 2955000 USD 2003-01-01 – 2003-12-31: 2955000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Coley Pharmaceutical Group, Inc. · 2003-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Capital Expenditure: 2955000 USD Concept: fundies:CapitalExpenditure Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197/explain?concept=fundies%3ACapitalExpenditure&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2955000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-06-061871.txt#10364 The citation records this snapshot. The page link may show a newer release later.	−USD 25.38 million Calculation and evidence -22425000 − 2955000 USD Exact free cash flow: -25380000 USD 2003-01-01 – 2003-12-31: -22425000 USD · Inspect Operating Cash Flow · Source 2003-01-01 – 2003-12-31: 2955000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Coley Pharmaceutical Group, Inc. · 2003-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Free cash flow: -25380000 USD Concept: free-cash-flow Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22425000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-06-061871.txt#10280 Input fundies:CapitalExpenditure: 2955000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-06-061871.txt#10364 The citation records this snapshot. The page link may show a newer release later.
2004 2004-01-01 – 2004-12-31	−USD 33.98 million Exact value Exact value: -33981000 USD 2004-01-01 – 2004-12-31: -33981000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Coley Pharmaceutical Group, Inc. · 2004-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Net Income: -33981000 USD Concept: fundies:NetIncome Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197/explain?concept=fundies%3ANetIncome&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:NetIncome: -33981000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#9952 The citation records this snapshot. The page link may show a newer release later.	−USD 27.72 million Exact value Exact value: -27718000 USD 2004-01-01 – 2004-12-31: -27718000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Coley Pharmaceutical Group, Inc. · 2004-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Operating Cash Flow: -27718000 USD Concept: fundies:OperatingCashFlow Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197/explain?concept=fundies%3AOperatingCashFlow&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -27718000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10134 The citation records this snapshot. The page link may show a newer release later.	USD 361,000 Exact value Exact value: 361000 USD 2004-01-01 – 2004-12-31: 361000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Coley Pharmaceutical Group, Inc. · 2004-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Capital Expenditure: 361000 USD Concept: fundies:CapitalExpenditure Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197/explain?concept=fundies%3ACapitalExpenditure&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 361000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10232 The citation records this snapshot. The page link may show a newer release later.	−USD 28.08 million Calculation and evidence -27718000 − 361000 USD Exact free cash flow: -28079000 USD 2004-01-01 – 2004-12-31: -27718000 USD · Inspect Operating Cash Flow · Source 2004-01-01 – 2004-12-31: 361000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Coley Pharmaceutical Group, Inc. · 2004-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Free cash flow: -28079000 USD Concept: free-cash-flow Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -27718000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10134 Input fundies:CapitalExpenditure: 361000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10232 The citation records this snapshot. The page link may show a newer release later.
2005 2005-01-01 – 2005-12-31	−USD 38.06 million Exact value Exact value: -38064000 USD 2005-01-01 – 2005-12-31: -38064000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Coley Pharmaceutical Group, Inc. · 2005-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Net Income: -38064000 USD Concept: fundies:NetIncome Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197/explain?concept=fundies%3ANetIncome&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38064000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#9952 The citation records this snapshot. The page link may show a newer release later.	USD 11.13 million Exact value Exact value: 11128000 USD 2005-01-01 – 2005-12-31: 11128000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Coley Pharmaceutical Group, Inc. · 2005-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Operating Cash Flow: 11128000 USD Concept: fundies:OperatingCashFlow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197/explain?concept=fundies%3AOperatingCashFlow&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 11128000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10134 The citation records this snapshot. The page link may show a newer release later.	USD 568,000 Exact value Exact value: 568000 USD 2005-01-01 – 2005-12-31: 568000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Coley Pharmaceutical Group, Inc. · 2005-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Capital Expenditure: 568000 USD Concept: fundies:CapitalExpenditure Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197/explain?concept=fundies%3ACapitalExpenditure&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 568000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10232 The citation records this snapshot. The page link may show a newer release later.	USD 10.56 million Calculation and evidence 11128000 − 568000 USD Exact free cash flow: 10560000 USD 2005-01-01 – 2005-12-31: 11128000 USD · Inspect Operating Cash Flow · Source 2005-01-01 – 2005-12-31: 568000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Coley Pharmaceutical Group, Inc. · 2005-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Free cash flow: 10560000 USD Concept: free-cash-flow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 11128000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10134 Input fundies:CapitalExpenditure: 568000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10232 The citation records this snapshot. The page link may show a newer release later.
2006 2006-01-01 – 2006-12-31	−USD 29.78 million Exact value Exact value: -29775000 USD 2006-01-01 – 2006-12-31: -29775000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Coley Pharmaceutical Group, Inc. · 2006-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Net Income: -29775000 USD Concept: fundies:NetIncome Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197/explain?concept=fundies%3ANetIncome&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29775000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#9952 The citation records this snapshot. The page link may show a newer release later.	−USD 35.68 million Exact value Exact value: -35678000 USD 2006-01-01 – 2006-12-31: -35678000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Coley Pharmaceutical Group, Inc. · 2006-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Operating Cash Flow: -35678000 USD Concept: fundies:OperatingCashFlow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197/explain?concept=fundies%3AOperatingCashFlow&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35678000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10134 The citation records this snapshot. The page link may show a newer release later.	USD 811,000 Exact value Exact value: 811000 USD 2006-01-01 – 2006-12-31: 811000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Coley Pharmaceutical Group, Inc. · 2006-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Capital Expenditure: 811000 USD Concept: fundies:CapitalExpenditure Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197/explain?concept=fundies%3ACapitalExpenditure&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 811000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10232 The citation records this snapshot. The page link may show a newer release later.	−USD 36.49 million Calculation and evidence -35678000 − 811000 USD Exact free cash flow: -36489000 USD 2006-01-01 – 2006-12-31: -35678000 USD · Inspect Operating Cash Flow · Source 2006-01-01 – 2006-12-31: 811000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Coley Pharmaceutical Group, Inc. · 2006-12-31 Coley Pharmaceutical Group, Inc. (edgar:1319197) Free cash flow: -36489000 USD Concept: free-cash-flow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-07T17:34:46Z Snapshot: ba1efece969b2bc0eb736023c7dae5f3ba8dc77de6339338dbcd3fbf077d99ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1319197?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35678000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10134 Input fundies:CapitalExpenditure: 811000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1319197/0001193125-07-050978.txt#10232 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

11 filings · 0 latest values · 0 originally reported values

Dataset published 2026-11-07. Source filing dates and reporting periods are shown separately.

Identifiers: 0001319197, 1319197, edgar:1319197

Coley Pharmaceutical Group, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2006 2006-01-01 – 2006-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation